Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Accumulated Expenses data on file, last reported at $6.1 million in Q1 2026.

• Quarterly Accumulated Expenses rose 744.34% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 744.34% YoY) and the FY2025 annual result came in at $6.0 million, up 168.04% from the prior year.
• Accumulated Expenses climbed to $6.1 million in Q1 2026 per VVOS's latest filing, from $6.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.1 million in Q1 2026 and bottomed at $724000.0 in Q1 2025.
• The 5-year median for Accumulated Expenses is $1.9 million (2023), against an average of $2.3 million.
• The widest annual swing landed in 2025, when Accumulated Expenses slumped 70.64%; it then surged 744.34% in 2026.
• Tracing VVOS's Accumulated Expenses over 5 years: stood at $1.9 million in 2022, then increased by 22.07% to $2.3 million in 2023, then slipped by 4.28% to $2.2 million in 2024, then soared by 168.04% to $6.0 million in 2025, then rose by 2.09% to $6.1 million in 2026.
• Per Business Quant, the three latest VVOS Accumulated Expenses figures stand at $6.1 million (Q1 2026), $6.0 million (Q4 2025), and $1.2 million (Q3 2025).

Peer Comparison